We aim to create value by providing talented entrepreneurs with the resources and tools to achieve success in transforming intellectual capital and specific knowledge into successful companies



Ysios news
02.04.19
Aura Biosciences Completes $40 Million Series D Financing

26.10.18
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

portfolio news
04.06.19
Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation

04.06.19
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia